Spark Investment Management LLC acquired a new stake in InVitae Corp (NASDAQ:NVTA) during the second quarter, Holdings Channel reports. The firm acquired 30,000 shares of the medical research company’s stock, valued at approximately $286,000.

A number of other large investors also recently added to or reduced their stakes in NVTA. Nationwide Fund Advisors raised its stake in InVitae Corp by 21.1% in the first quarter. Nationwide Fund Advisors now owns 17,121 shares of the medical research company’s stock valued at $189,000 after buying an additional 2,987 shares in the last quarter. Donald L. Hagan LLC raised its stake in InVitae Corp by 30.0% in the second quarter. Donald L. Hagan LLC now owns 13,000 shares of the medical research company’s stock valued at $124,000 after buying an additional 3,000 shares in the last quarter. American International Group Inc. raised its stake in InVitae Corp by 31.3% in the first quarter. American International Group Inc. now owns 17,174 shares of the medical research company’s stock valued at $190,000 after buying an additional 4,090 shares in the last quarter. Credit Suisse AG raised its stake in InVitae Corp by 22.9% in the first quarter. Credit Suisse AG now owns 25,178 shares of the medical research company’s stock valued at $279,000 after buying an additional 4,694 shares in the last quarter. Finally, Teachers Advisors LLC raised its stake in InVitae Corp by 18.3% in the fourth quarter. Teachers Advisors LLC now owns 42,372 shares of the medical research company’s stock valued at $336,000 after buying an additional 6,547 shares in the last quarter.

InVitae Corp (NASDAQ NVTA) opened at 9.90 on Tuesday. The stock’s market cap is $431.09 million. InVitae Corp has a 12 month low of $5.76 and a 12 month high of $11.88. The stock’s 50 day moving average price is $9.55 and its 200-day moving average price is $9.82.

InVitae Corp (NASDAQ:NVTA) last posted its quarterly earnings results on Monday, August 7th. The medical research company reported ($0.66) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.64) by $0.02. InVitae Corp had a negative net margin of 199.20% and a negative return on equity of 153.27%. The business had revenue of $14.34 million during the quarter, compared to analysts’ expectations of $13.31 million. During the same quarter last year, the firm earned ($0.77) earnings per share. The firm’s quarterly revenue was up 157.0% compared to the same quarter last year. Equities research analysts predict that InVitae Corp will post ($2.40) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “30,000 Shares in InVitae Corp (NVTA) Acquired by Spark Investment Management LLC” was first reported by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/30000-shares-in-invitae-corp-nvta-acquired-by-spark-investment-management-llc/1488750.html.

Several research firms have commented on NVTA. BidaskClub lowered InVitae Corp from a “hold” rating to a “sell” rating in a research report on Thursday, July 27th. Zacks Investment Research lowered InVitae Corp from a “hold” rating to a “sell” rating in a research report on Tuesday, July 18th. ValuEngine upgraded InVitae Corp from a “strong sell” rating to a “sell” rating in a research report on Friday, June 2nd. Finally, J P Morgan Chase & Co reiterated an “overweight” rating and set a $15.00 target price (up previously from $14.00) on shares of InVitae Corp in a research report on Wednesday, August 9th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $12.94.

About InVitae Corp

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.

Want to see what other hedge funds are holding NVTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for InVitae Corp (NASDAQ:NVTA).

Institutional Ownership by Quarter for InVitae Corp (NASDAQ:NVTA)

Receive News & Ratings for InVitae Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.